China Expands its EV Footprint on the World Stage

As Chinese automobile manufacturer Geely, the parent company behind Volvo and Daimler AG, plans to launch its sub-brand of luxury electric vehicles, a possible competitor to Tesla’s growing footprint, the country appears poised to dominate the EV industry.

Since the early ‘90s, China has ramped up its annual automobile production capacity. In 2001, after joining the World Trade Organization, it increased its production significantly, and today, based on 2019 research from the global trade group, International Organization of Motor Vehicle Manufacturer, or OICA, and 2020 research from Statista, China remains the world’s forerunner, producing nearly 26 million cars in 2020. Now, the focus is on scaling electric vehicle manufacturing, producing autos with the latest technology.

Host Daniel Litwin, the voice of B2B at MarketScale, was joined by Qasim Khan, Deputy Manager of EqualOcean, a China-focused investment research firm with a concentration on China’s innovation, to talk about the investment policies that have allowed the country to scale its booming EV production, plus what the future holds for China and the global supply chain.

 

In his role at EqualOcean, Khan oversees the coverage of the auto and consumer sectors. Litwin hosts and produces podcasts with industry and thought leaders. Together they offer a world of insights on the topic of China’s EV expansion.

“If we look at action specifically around the EV market, much of China’s recent market growth could be attributed to China’s Climate Policy policy action to encourage EV use and manufacturing,” said Khan, referring to initiatives such as EV consumer subsidies, new energy vehicle mandates and credits, and over 500,000 public EV charging outlets.

And since 2018, China has moved its auto production industry onto the world stage, allowing international players like Tesla, Volkswagon, and BMW to expand their manufacturing footprint in China.

Questions remain as to how China is positioning itself to maximize those investments, and whether more international partnerships are on the table.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

personal branding
Personal Branding Now Drives B2B Success, Customer Trust, and Competitive Advantage
December 5, 2025

Personal branding has rapidly shifted from a “nice-to-have” to a strategic imperative in B2B marketing, reshaping how companies communicate, differentiate, and build trust. As industries evolve and professionals take on more dynamic, multi-stream careers, visibility and authenticity have become critical assets. Key findings from the Edelman + LinkedIn Thought Leadership Impact Report show that…

Read More
IT
Real-World IT Practices Are Streamlining AV Deployments and Raising the Bar for Consistency
December 4, 2025

For years, the AV industry has discussed the long-anticipated convergence with IT—but that shift is no longer theoretical. With cloud adoption accelerating, hybrid work normalizing, and organizations rebuilding digital infrastructure after years of rapid change, AV systems now sit squarely on the IT backbone. In fact, the majority of newly upgraded conference rooms require network-centric…

Read More
ROI
ROI Case Study
December 3, 2025

Denials are no longer a slow leak in the revenue cycle—they’re a fast-moving, rule-shifting game controlled by payers, and hospitals that don’t model denial patterns in real time end up budgeting around losses they could have prevented. PayerWatch’s four-digit, client-verified ROI in 2024 shows what happens when a hospital stops reacting claim by…

Read More
coverage
Clip 2 – Fighting for Coverage: One Patient’s Story
December 3, 2025

Health insurers love to advertise themselves as guardians of care, but the real story often begins when a patient’s life no longer fits neatly into a spreadsheet. In oncology especially, “coverage” isn’t a bureaucratic checkbox—it’s the fragile bridge between a treatment that finally works and a relapse that can undo years of grit…

Read More